Yumanity Therapeutics acquires Kineta, Inc., and with it KVA12.1 , a potential best-in-class VISTA blocking immunotherapy
Yumanity Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced it has entered into a definitive agreement by which Kineta, Inc., will become a wholly-owned subsidiary of Yumanity in an all-stock transaction, resulting in a combined publicly traded company re-named Kineta, Inc., that will focus on immuno-oncology and continue Yumanity’s ongoing research collaboration with Merck & Co. in amyotrophic lateral sclerosis and frontotemporal lobar dementia.
Upon completion of the proposed merger, on a pro forma basis and based upon the number of Yumanity shares to be issued in the proposed merger, current Kineta stockholders are expected to own approximately 85% of the combined company and current Yumanity stockholders are expected to own approximately 15% of the combined company. Kineta’s IND-ready, lead asset is KVA12.1, is a potential best-in-class VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins